- My News
- All News
- Most Popular
Terumo has entered an agreement to jointly develop Diabeloop's DBLG1 automated insulin delivery (AID) solution, which will be integrated with the Japanese company's MEDISAFE WITH insulin patch pump to help insulin-dependent patients manage their diabetes, the companies announced Monday. The deal also gives Terumo exclusive distributor rights for the product in the Japanese market.
"Diabeloop's algorithm is cutting edge technology that is being launched in Europe," remarked Yoshiya Kikawa, general manager of diabetes management and consumer healthcare at Terumo, adding that "by combining this technology, it will be possible to realise the AID system based on MEDISAFE WITH." Diabeloop CEO Erik Huneker said "we want to provide choice and access to people living with diabetes, and interoperability of our solution, with multiple pumps and in more countries, is key to this."
DBLG1, an algorithm hosted in a dedicated handset, is connected with a continuous glucose monitoring device and an insulin pump in a closed-loop system. "Diabeloop's artificial intelligence (AI) analyses blood glucose data, calculates the right dose of insulin to be administered and gives the order to the pump to deliver it, thus automating the treatment," the companies said.
Meanwhile, Terumo noted that MEDISAFE WITH is the only insulin patch pump available in Japan since its launch in 2018. With the device, insulin is subcutaneously administered through a cannula attached to the patch, while basal and bolus settings can be adjusted using a remote control when needed, independently from the AID system.
Under the agreement, whose financial terms were not disclosed, Diabeloop and Terumo are planning to conduct a clinical study following the integration of their technologies and will prepare for regulatory approval in Japan. The companies indicated that they are also considering future distribution to other countries.
To ensure you don't miss other Top Stories like these and news on key medtech industry developments, sign up for our free daily e-newsletter here.
Did you like this article?